Market open

Cassava Sciences/$SAVA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Ticker

$SAVA
Trading on

Industry

Pharmaceuticals

Employees

29

Cassava Sciences Metrics

BasicAdvanced
$126M
-
-$1.37
-1.10
-

$126M

-1.1

$42.20

$2.23

3.5M

3.551

2.612

-45.63%

-10.98%

0.75

0.75

-1.505

-40.16%

34.57%

What the Analysts think about Cassava Sciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Cassava Sciences stock.
0.00%20.00%40.00%60.00%80.00%100.00%JulAugSeptOctNovDecJanFebMarAprMayJun

Cassava Sciences Financial Performance

$0$10B$20B$30B$40B$50B$60BQ4 23Q1 24Q2 24Q3 24

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Cassava Sciences Earnings Performance

$0.00$1.00$2.00$3.00Q4 23BeatQ1 24BeatQ2 24BeatQ3 24BeatQ4 24-

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SAVA

$

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Cassava Sciences stock?

Cassava Sciences (SAVA) has a market cap of $126M as of January 22, 2025.

What is the P/E ratio for Cassava Sciences stock?

The price to earnings (P/E) ratio for Cassava Sciences (SAVA) stock is 0 as of January 22, 2025.

Does Cassava Sciences stock pay dividends?

No, Cassava Sciences (SAVA) stock does not pay dividends to its shareholders as of January 22, 2025.

When is the next Cassava Sciences dividend payment date?

Cassava Sciences (SAVA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cassava Sciences?

Cassava Sciences (SAVA) has a beta rating of -1.1. This means that it has an inverse relation to market volatility.

Can we use optional cookies? View our Cookie Policy for details.

pixel